Endometrial carcinosarcoma. Issue 2 (30th December 2022)
- Record Type:
- Journal Article
- Title:
- Endometrial carcinosarcoma. Issue 2 (30th December 2022)
- Main Title:
- Endometrial carcinosarcoma
- Authors:
- Bogani, Giorgio
Ray-Coquard, Isabelle
Concin, Nicole
Ngoi, Natalie Yan Li
Morice, Philippe
Caruso, Giuseppe
Enomoto, Takayuki
Takehara, Kazuhiro
Denys, Hannelore
Lorusso, Domenica
Coleman, Robert
Vaughan, Michelle M
Takano, Masashi
Provencher, Diane Michele
Sagae, Satoru
Wimberger, Pauline
Póka, Robert
Segev, Yakir
Kim, Se Ik
Kim, Jae-Weon
Candido dos Reis, Francisco Jose
Ramirez, Pedro T
Mariani, Andrea
Leitao, Mario
Makker, Vicky
Abu-Rustum, Nadeem R
Vergote, Ignace
Zannoni, Gianfranco
Tan, David
McCormack, Mary
Paolini, Biagio
Bini, Marta
Raspagliesi, Francesco
Benedetti Panici, Pierluigi
Di Donato, Violante
Muzii, Ludovico
Colombo, Nicoletta
Pignata, Sandro
Scambia, Giovanni
Monk, Bradley J
… (more) - Abstract:
- Abstract : Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The clinical presentation and diagnostic work-up roughly align with those of the more common endometrioid counterpart, although endometrial carcinosarcoma is more frequently diagnosed at an advanced stage. Endometrial carcinosarcoma is not a single entity but encompasses different histological subtypes, depending on the type of carcinomatous and sarcomatous elements. The majority of endometrial carcinosarcomas are characterized by p53 abnormalities. The proportion of POLE and microsatellite instablity-high (MSI-H) is directly related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components. The management of non-metastatic disease is based on a multimodal approach with optimal surgery followed by (concomitant or sequential) chemotherapy and radiotherapy, even for early stages. Palliative chemotherapy is recommended in the metastatic or recurrent setting, with carboplatin/paclitaxel doublet being the first-line regimen. Although the introduction of immunotherapy plus/minus a tyrosine kinase inhibitor shifted the paradigm of treatment of patients with recurrent endometrial cancer, patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or the combination. However, the US Food and Drug Administration (FDA) andAbstract : Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The clinical presentation and diagnostic work-up roughly align with those of the more common endometrioid counterpart, although endometrial carcinosarcoma is more frequently diagnosed at an advanced stage. Endometrial carcinosarcoma is not a single entity but encompasses different histological subtypes, depending on the type of carcinomatous and sarcomatous elements. The majority of endometrial carcinosarcomas are characterized by p53 abnormalities. The proportion of POLE and microsatellite instablity-high (MSI-H) is directly related to the epithelial component, being approximately 25% and 3% in endometrioid and non-endometrioid components. The management of non-metastatic disease is based on a multimodal approach with optimal surgery followed by (concomitant or sequential) chemotherapy and radiotherapy, even for early stages. Palliative chemotherapy is recommended in the metastatic or recurrent setting, with carboplatin/paclitaxel doublet being the first-line regimen. Although the introduction of immunotherapy plus/minus a tyrosine kinase inhibitor shifted the paradigm of treatment of patients with recurrent endometrial cancer, patients with endometrial carcinosarcoma were excluded from most studies evaluating single-agent immunotherapy or the combination. However, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved the use of pembrolizumab and lenvatinib in endometrial cancer (all histotypes) after progression on chemotherapy and single-agent immunotherapy in MSI-H cancers. In the era of precision medicine, emerging knowledge on molecular endometrial carcinosarcoma is opening new promising therapeutic options for more personalized treatment. The present review outlines state-of-the-art knowledge and future directions for patients with endometrial carcinosarcoma. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 33:Issue 2(2023)
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 33:Issue 2(2023)
- Issue Display:
- Volume 33, Issue 2 (2023)
- Year:
- 2023
- Volume:
- 33
- Issue:
- 2
- Issue Sort Value:
- 2023-0033-0002-0000
- Page Start:
- 147
- Page End:
- 174
- Publication Date:
- 2022-12-30
- Subjects:
- uterine cancer -- carcinosarcoma -- genital neoplasms, female
Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2022-004073 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26034.xml